Seller record · Telehealth service

NEUVÉ

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 4 of 8 criteria. S3, pharmacy identification: The pages say medication is prepared by a state-licensed pharmacy among vetted US pharmacy partners, and no pharmacy is named in the footer, the answers, the terms or the policies. 3 more criteria also fail; see the table below.

At a glance

NEUVÉTelehealth service

4/8criteria passed
Price
Semaglutide first month $149, then $179 a month; tirzepatide first month $199, then $240; its billing policy says medication is billed separately
Sells
compounded semaglutide (injectable microdose, injectable, oral RDT), and 18 more
FDA letters
None on file
Visit NEUVÉSee all eight dispositions

Telehealth service. Passes 4 of 8 criteria. Recorded against Standard v1.1.

An Arizona telehealth platform selling compounded semaglutide and tirzepatide as injections and oral tablets, a long list of compounded peptides including tesamorelin and BPC-157, and hormone therapy, with a first-month price on nearly every product, though its own billing policy says the medication is billed separately by an unnamed clinical partner. It prints a city but no street address and names no filling pharmacy.

Operating entity Neuve Health, LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSNEUVÉ's weight loss page; NEUVÉ's website
S2Prescription gatingPASSNEUVÉ's quiz page; NEUVÉ's weight loss page; NEUVÉ's website
S3Pharmacy identificationFAILNEUVÉ's website; NEUVÉ's FAQ; NEUVÉ's terms
S4Compounding disclosureFAILNEUVÉ's weight loss page; NEUVÉ's pricing page; NEUVÉ's peptides page
S5Analytical documentationFAILNEUVÉ's pricing page; NEUVÉ's peptides page
S6Business addressFAILNEUVÉ's website; NEUVÉ's terms; NEUVÉ's privacy page; NEUVÉ's financial policy
S7Price disclosurePASSNEUVÉ's pricing page; NEUVÉ's weight loss page; NEUVÉ's financial policy; NEUVÉ's tesamorelin product page
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA U.S. licensed clinician reviews each intake and decides whether treatment is medically appropriate, and a prescription is never guaranteed.Source: NEUVÉ's weight loss page; NEUVÉ's website.
S2PASSThe quiz button opens an intake whose first screen asks what brings the buyer to the service, and the home page says no card is required to start.Source: NEUVÉ's quiz page; NEUVÉ's weight loss page; NEUVÉ's website.
S3FAILThe pages say medication is prepared by a state-licensed pharmacy among vetted US pharmacy partners, and no pharmacy is named in the footer, the answers, the terms or the policies.Source: NEUVÉ's website; NEUVÉ's FAQ; NEUVÉ's terms.
S4FAILThe weight loss and pricing pages sell compounded semaglutide and tirzepatide with no statement that a compounded drug is not FDA-approved. Only the peptide pages say that many compounded preparations are not FDA-approved finished products.Source: NEUVÉ's weight loss page; NEUVÉ's pricing page; NEUVÉ's peptides page.
S5FAILNo certificate of analysis or lot document is published on the product pages, the pricing page or the policies.Source: NEUVÉ's pricing page; NEUVÉ's peptides page.
S6FAILThe footer, the terms, the privacy policy and the refund and financial policies give Neuve Health, LLC in Gilbert, Arizona with no street address.Source: NEUVÉ's website; NEUVÉ's terms; NEUVÉ's privacy page; NEUVÉ's financial policy.
S7PASSCompounded semaglutide microdose injections at $179 a month with a first month at $149, standard injections at $219 with a first month at $189, and oral tablets at $329 with a first month at $279. Compounded tirzepatide microdose injections at $240 a month with a first month at $199, standard injections at $349 with a first month at $299, and oral tablets at $279 with a first month at $249. NAD+ injections at $199 with a first month at $169, sermorelin at $249 with a first month at $229, GHK-Cu at $219 with a first month at $189, PT-141 at $229 with a first month at $199 and tesamorelin at $299 with a first month at $279. The seller prints two accounts of what these prices cover: the weight loss page heads the price cards all-in monthly pricing, while the same page and the pricing page call the figures starting-at estimates and say medication, labs and supplies are billed separately by an independent clinical partner, and the financial policy says the seller charges directly only for its Core, Plus and Premium memberships, which carry no printed price.Source: NEUVÉ's pricing page; NEUVÉ's weight loss page; NEUVÉ's financial policy; NEUVÉ's tesamorelin product page.
S8PASSNo FDA warning letter names NEUVÉ or Neuve Health, LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide (injectable microdose, injectable, oral RDT), compounded tirzepatide (injectable microdose, injectable, oral RDT), NAD+ injection, NAD+ nasal spray, sermorelin, tesamorelin, GHK-Cu injection, GHK-Cu topical cream, BPC-157, TB-500, stacks of BPC-157, TB-500, GHK-Cu and KPV, CJC-1295 + ipamorelin, PT-141, glutathione injection, thymosin alpha-1, MOTS-c, epithalon, testosterone therapy, estradiol and progesterone.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+Who sells glutathioneWho sells PT-141Who sells GHK-CuWho sells tesamorelinWho sells BPC-157Who sells TB-500Who sells MOTS-cWho sells epitalonWho sells ipamorelin

Visit NEUVÉ

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.